PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
PVCT was delisted on the 13th of October, 2016.
5 hedge funds and large institutions have $16K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2020 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% more capital invested
Capital invested by funds: $8K → $16K (+$8K)
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Academy Capital Management
Waco,
Texas
|
+$1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HFBOT
1
Home Federal Bank of Tennessee
Knoxville,
Tennessee
| $9K | – | – | – |
|
|
LDB
2
Lee, Danner & Bass
Nashville,
Tennessee
| $4K | – | – | – |
|
|
CCB
3
Cutter & Co Brokerage
Ballwin,
Missouri
| $2K | – | – | – |
|
|
ACM
4
Academy Capital Management
Waco,
Texas
| $1K | +$1K | +20,000 | New |
|
|
5
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -21,657 | Closed |
|
PVCT Hedge Fund Activity: Q3 2020 in Review
5 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q3 2020, worth a combined $16K — up 100% from $8K a quarter earlier.
Fund positioning in PVCT was balanced in Q3 2020: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Academy Capital Management, opening a new position worth an estimated $1K. The largest seller was CAPTRUST Financial Advisors, exiting entirely with an estimated $1K sold.
- 5 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $16K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q3 2020, up 100% quarter-over-quarter.
- 1 fund opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q3 2020 and 1 closed out, a net change of 0 holders.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q3 2020 was Academy Capital Management, an estimated $1K added.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q3 2020 was CAPTRUST Financial Advisors, an estimated $1K sold.
Based on aggregated 13F filings for Q3 2020.